Meeting
2017 ASCO Annual Meeting
Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas.
Authors
Frederick C. Eilber
University of California, Los Angeles, Los Angeles, CA
Frederick C. Eilber , Kamalesh Kumar Sankhala , Sant P. Chawla , Victoria S. Chua-Alcala , Erlinda Maria Gordon , Doris Quon , Katherine Kim , Shanta Chawla , Nancy Wu , Scott Wieland , Daniel J. Levitt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02235701
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11051)
DOI
10.1200/JCO.2017.35.15_suppl.11051
Abstract #
11051
Poster Bd #
374
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
First Author: Erlinda Maria Gordon
Poster
2021 ASCO Annual Meeting
Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.
First Author: Roberta Sanfilippo
Poster
2020 ASCO Virtual Scientific Program
A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma.
First Author: Michael B. Livingston
Poster
2018 ASCO Annual Meeting
Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).
First Author: Eoghan Ruadh Malone